Skip to Main Content

INFORMATION FOR

Botox type A for the prevention of POAF in open-chest cardiac surgery

Conditions

Diseases of the Cardiovascular System

Phase II

What is the purpose of this trial?

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.

  • Trial with
    Allergan Sales, Inc.
  • Start Date
    05/15/2021
  • End Date
    10/15/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000028539